Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

Anja Schweizer1, Sylvie Dejager2, James E Foley3, Wolfgang Kothny31Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharma SAS, Rueil-Malmaison, France; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USAAim: Analyzing safety aspects of a drug from individual studies can lead to difficult-...

Full description

Bibliographic Details
Main Authors: Schweizer A, Dejager S, Foley JE, Kothny W
Format: Article
Language:English
Published: Dove Medical Press 2011-02-01
Series:Vascular Health and Risk Management
Subjects:
type 2 diabetes
dipeptidyl peptidase-4
edema
safety
vildagliptin
Online Access:https://www.dovepress.com/assessing-the-general-safety-and-tolerability-of-vildagliptin-value-of-peer-reviewed-article-VHRM

Internet

https://www.dovepress.com/assessing-the-general-safety-and-tolerability-of-vildagliptin-value-of-peer-reviewed-article-VHRM

Similar Items